Forte Biosciences (FBRX) Tax Provisions (2018 - 2026)

Forte Biosciences (FBRX) posted quarterly Tax Provisions of $373000.0 for Q1 2026, up 121.95% quarter-over-quarter from -$1.7 million in Q4 2018.

Forte Biosciences (FBRX) Tax Provisions (2018 - 2026) Analysis & Trends

Forte Biosciences (FBRX) has reported Tax Provisions for 2 consecutive years, with $373000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Tax Provisions changed N/A year-over-year to $373000.0; the TTM figure through Mar 2026 stood at -$1.3 million (down 597.89% YoY), while the FY2025 annual figure was $1.0 million, up 113.92% from the prior year.
Tax Provisions improved to $373000.0 in Q1 2026 per FBRX's latest filing, from -$1.7 million in the prior quarter.
Across five years, Tax Provisions topped out at $373000.0 in Q1 2026 and bottomed at $373000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	59.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	75.45 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	267.73
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.31 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	1.90 Mn
10	Forte Biosciences	1.63 Bn	1.28 Bn	-	193,000.00

Download Data